Holen Sie sich die Stockscreener-App
345.82
0.25%
0.86
Handel nachbörslich:
345.82
Schlusskurs vom Vortag:
$344.96
Offen:
$346.34
24-Stunden-Volumen:
199.92K
Relative Volume:
0.51
Marktkapitalisierung:
$10.24B
Einnahmen:
$417.30M
Nettoeinkommen (Verlust:
$225.03M
KGV:
46.22
EPS:
7.4815
Netto-Cashflow:
$237.38M
1W Leistung:
+2.72%
1M Leistung:
-2.91%
6M Leistung:
+35.64%
1J Leistung:
+114.60%
1-Tages-Spanne:
$341.90
$347.74
1-Wochen-Bereich:
$332.44
$353.84
52-Wochen-Spanne:
$159.24
$382.54
Krystal Biotech Inc Stock (KRYS) Company Profile
Firmenname
Krystal Biotech Inc
Sektor
Branche
Telefon
(412) 586-5830
Adresse
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
345.82 | 10.24B | 417.30M | 225.03M | 237.38M | 7.4815 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-05 | Eingeleitet | Jefferies | Buy |
| 2024-08-06 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Eingeleitet | Citigroup | Buy |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2023-02-28 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-25 | Herabstufung | Goldman | Buy → Neutral |
| 2022-01-18 | Eingeleitet | BofA Securities | Buy |
| 2021-07-20 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-18 | Eingeleitet | B. Riley FBR | Buy |
| 2020-06-04 | Eingeleitet | Evercore ISI | Outperform |
| 2019-09-24 | Eingeleitet | Goldman | Neutral |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-24 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-06-24 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-30 | Eingeleitet | Guggenheim | Buy |
| 2018-09-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Krystal Biotech Inc Aktie (KRYS) Neueste Nachrichten
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo! Finance Canada
Here's How Much $1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today - Benzinga
KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism - Stocktwits
KRYS Reinstated by Goldman Sachs -- Price Target Announced at $4 - gurufocus.com
Krystal Biotech stock initiated at buy by Goldman Sachs - Investing.com Nigeria
KRYS Looks 0.1% Overvalued on GF Value™ - gurufocus.com
Goldman Sachs Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $441 - Moomoo
Precision Trading with Krystal Biotech Inc. (KRYS) Risk Zones - Stock Traders Daily
KRYS Maintained by B of A Securities -- Price Target Raised to $400 - gurufocus.com
BofA Securities Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $400 - Moomoo
KRYSTAL BIOTECH, INC. : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $400 FROM $392 - Bitget
BofA Adjusts Price Target on Krystal Biotech to $400 From $392, Keeps Buy Rating - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: A Look At Its 14.36% Potential Upside - DirectorsTalk Interviews
Krystal Biotech (NASDAQ: KRYS) Grants Director Sutherland Everett Rand 1,658 Derivative Securities - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Catherine Mazzacco - Kalkine Media
Rossi Dino A Granted 1,658 Derivative Securities of Krystal Biotech, Inc. on September 14, 2026 - Kalkine Media
Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Mason Christopher - Kalkine Media
Director at Krystal Biotech (KRYS) gets new stock options and RSUs - Stock Titan
Krystal Biotech (KRYS) board member receives new options and RSUs - Stock Titan
Krystal Biotech | 4: Statement of changes in beneficial ownership of securities-Director ROSSI DINO A - Moomoo
(KRYS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
What Put Krystal Biotech (KRYS) in Focus? - Kalkine Media
Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada
KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView
Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com
Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga
Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - kalkinemedia.com
Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media
Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com
Krystal Biotech, Inc. (KRYS) Stock Analysis: Unveiling a 7.47% Potential Upside with Promising Genetic Medicine Innovations - DirectorsTalk Interviews
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock By Investing.com - Investing.com South Africa
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock By Investing.com - Investing.com Australia
Krystal Biotech CEO Krish S. Krishnan sells $8.98m in company stock - Investing.com Nigeria
Krystal Biotech president, R&D Suma Krishnan sells $8.98m in stock - Investing.com Nigeria
Krystal Biotech(KRYS.US) 10% Shareholder Sells US$8.98 Million in Common Stock - Moomoo
Krystal Biotech (KRYS) R&D head sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) CEO sells 25,000 shares under trading plan - Stock Titan
Krystal Biotech (NASDAQ: KRYS) holder to sell 25,000 founders shares - Stock Titan
Krystal Biotech (KRYS) insider moves to sell 2017 shares in a multimillion-dollar deal - Stock Titan
Krystal Biotech stock steadies as regulatory debate over Vyjuvek intensifies - ad-hoc-news.de
Krystal Biotech | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally? - TradingView
Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference - The Manila Times
Krystal Biotech to Participate in 2026 Cantor Global Healthcare Conference - Quiver Quantitative
A healthcare conference webcast is set for Sept. 10 in New York - Stock Titan
Krystal Biotech stock gains on solid Q2 2026 Vyjuvek growth - ad-hoc-news.de
Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings And 9.54% Potential Upside - DirectorsTalk Interviews
Krystal Biotech, Inc. (KRYS) Stock Analysis: Discovering a 11% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Krystal Biotech Stock Soars 16% in Three Months: Here's Why - Eastern Progress
Finanzdaten der Krystal Biotech Inc-Aktie (KRYS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):